Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | PREP | P48147 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911108 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL660057 | 0.94 | CHRM2 (0.67) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL30128274 | 0.94 | CHRM2 (0.67) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL26970792 | 0.94 | CHRM2 (0.67) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL18682177 | 0.94 | CHRM2 (0.67) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL16421281 | 0.94 | CHRM2 (0.67) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL18662292 | 0.94 | CHRM2 (0.67) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL1029630 | 0.94 | CHRM2 (0.67) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL20635018 | 0.94 | CHRM2 (0.67) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL1027350 | 0.94 | CHRM2 (0.67) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| EP-1934212-A1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-06-25 | — | — | EP | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039563-A1 | 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | AZI2, TPMT, TET3 | CHRM2 1569/4885CHRM1 1450/4885CHRM3 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.